[1]
G. Lazarus, J. Audrey, and A. Iskandar, “Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review”, Oncol, vol. 13, no. 2, Oct. 2019.